Story
Johnson & Johnson Proposes $5.5 Billion Settlement for Talc-Related Ovarian Cancer Lawsuits
Summary
The healthcare giant has offered to pay $5.5 billion to resolve the majority of the 76,000 remaining ovarian cancer claims linked to its talc products, contingent on 95% claimant approval.
Johnson & Johnson (NYSE: JNJ) on Monday announced a proposed agreement to pay $5.5 billion to resolve the vast majority of its remaining U.S. lawsuits alleging its talc-based products caused ovarian cancer. The settlement is contingent upon securing agreement from at least 95% of the claimants.
Details of the Agreement
The proposed deal aims to conclude more than 15 years of litigation by settling approximately 76,000 outstanding claims currently consolidated in federal multidistrict litigation (MDL) and various state courts. Johnson & Johnson stated that this path provides an efficient resolution for all parties.
Under the terms outlined by the company, the payment structure would be staggered:
- The first payment, not to exceed $3 billion, would be made in 2027.
- No additional payments would be due before 2028.
Legal and Corporate Context
AdThis settlement offer follows a recent ruling in the federal MDL court that questioned the ability of plaintiffs to scientifically prove that the company's talc products were the specific cause of any individual's ovarian cancer. According to J&J, plaintiffs had withdrawn their causation experts in two key bellwether cases just before the court ordered them to justify why the remaining claims should not be dismissed.
While proposing the settlement to eliminate the costs and uncertainty of continued litigation, Johnson & Johnson reiterated its long-held position that its talc products are safe. The company maintains that decades of scientific research support that its cosmetic talc does not contain asbestos or cause cancer.
Market and Product Background
The ongoing legal battle has been a significant overhang for the company for years. In 2023, Johnson & Johnson discontinued the sale of its talc-based Johnson's Baby Powder globally, switching to a cornstarch-based formula.
Following the spinoff of its consumer health business into the publicly traded company Kenvue, Johnson & Johnson retained all liabilities related to the talc litigation. This proposed settlement represents a significant step toward resolving one of the largest and most complex mass tort litigations in U.S. history, potentially removing a major source of uncertainty for investors.
Read next
More on Stocks
Apple Ordered to Pay Record $5.7 Billion in Haptic Patent Case, Plans to Appeal
A U.S. jury found Apple's Taptic Engine infringed on two patents held by Taction, ordering a landmark $5.7 billion payment. The tech giant has stated it will appeal the verdict.
Northern Star Rejects Takeover Overture From Gold Fields, Bloomberg Reports
South Africa's Gold Fields Ltd. recently approached Australia's Northern Star Resources about a potential acquisition, but the offer was rejected, according to a report. The move comes as Northern Star faces pressure from an activist investor and deals with operational challenges.
European Telecoms Face AI-Driven Price Pressure, Bank of America Warns
Bank of America analysts report that while AI agents could increase customer churn for European telecom operators by simplifying price comparisons, the technology also offers powerful tools for sales and personalized customer retention.
ShinyHunters Hackers Renew Attacks on Oracle PeopleSoft Flaw, Google's Mandiant Reports
Google's cybersecurity unit, Mandiant, reports that the hacking group ShinyHunters has resumed and adapted its exploitation of a known vulnerability in Oracle's PeopleSoft enterprise software, targeting organizations that failed to apply a full security patch.